How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Chemical Research in Toxicology

• Publication date

  2017-01-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1021/acs.chemrestox.6b00357PMID 27775332
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism of isoniazid‐induced hepatotoxicity: then and now

  2016cited by this paper
• Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development.

  2016cited by this paper
• Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

  2016cited by this paper
• Protein Targets of Isoniazid-Reactive Metabolites in Mouse Liver in Vivo.

  2016cited by this paper
• Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells

  2016cited by this paper
• Immunology in the liver — from homeostasis to disease

  2016cited by this paper
• Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury

  2016cited by this paper
• Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.

  2016cited by this paper
• NLRP3 inflammasome and its inhibitors: a review

  2015cited by this paper
• The Roles of Mitochondrial Damage-Associated Molecular Patterns in Diseases

  2015cited by this paper
• Mechanisms of inflammasome activation: recent advances and novel insights.

  2015cited by this paper
• Inflammasomes: mechanism of action, role in disease, and therapeutics

  2015cited by this paper
• Treatment of PD‐1−/− mice with amodiaquine and anti‐CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients

  2015cited by this paper
• DAMPs from Cell Death to New Life

  2015cited by this paper
• Toxicity patterns with immunomodulating antibodies and their combinations.

  2015cited by this paper
• The Combination of Anti-CTLA-4 and PD1-/- Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury.

  2015cited by this paper
• Acute generalized exanthematous pustulosis (AGEP): A review and update.

  2015cited by this paper
• Comparative analysis of portal hepatic infiltrating leucocytes in acute drug‐induced liver injury, idiopathic autoimmune and viral hepatitis

  2015cited by this paper
• Endoplasmic reticulum stress in immunity.

  2015cited by this paper
• Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors

  2015cited by this paper
• Diagnosis and classification of drug-induced autoimmunity (DIA).

  2014cited by this paper
• Detection of anti‐isoniazid and anti–cytochrome P450 antibodies in patients with isoniazid‐induced liver failure

  2014cited by this paper
• Bypassing the compromised mitochondrial electron transport with methylene blue alleviates efavirenz/isoniazid-induced oxidant stress and mitochondria-mediated cell death in mouse hepatocytes

  2014cited by this paper
• Abacavir forms novel cross-linking abacavir protein adducts in patients.

  2014cited by this paper
• Activation of inflammasomes by agents causing idiosyncratic skin reactions: a possible biomarker.

  2014cited by this paper
• Expression of Concern: The functions of HMGB1 depend on molecular localization and post‐translational modifications

  2014cited by this paper
• Human drug‐induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump

  2014cited by this paper
• Mild isoniazid-induced liver injury in humans is associated with an increase in Th17 cells and T cells producing IL-10.

  2014cited by this paper
• Ambiguities in NLRP3 inflammasome regulation: is there a role for mitochondria?

  2014cited by this paper
• Recommendations for HLA‐B*15:02 and HLA‐A*31:01 genetic testing to reduce the risk of carbamazepine‐induced hypersensitivity reactions

  2014cited by this paper
• The Role of HMGB1 in the Pathogenesis of Inflammatory and Autoimmune Diseases

  2014cited by this paper
• Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management.

  2014cited by this paper
• Idiosyncratic Adverse Drug Reactions: Current Concepts

  2013cited by this paper
• Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

  2013cited by this paper
• Pharmacogenomics of adverse drug reactions

  2013cited by this paper
• At the Bedside: CTLA‐4‐ and PD‐1‐blocking antibodies in cancer immunotherapy

  2013cited by this paper
• ER stress-induced cell death mechanisms.

  2013cited by this paper
• Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury

  2013cited by this paper
• Oxidative bioactivation of abacavir in subcellular fractions of human antigen presenting cells.

  2013cited by this paper
• β-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis.

  2013cited by this paper
• Isoniazid-induced cell death is precipitated by underlying mitochondrial complex I dysfunction in mouse hepatocytes.

  2013cited by this paper
• Hepatotoxicity with combination of vemurafenib and ipilimumab.

  2013cited by this paper
• Human leukocyte antigen (HLA)‐B*57:01‐restricted activation of drug‐specific T cells provides the immunological basis for flucloxacillin‐induced liver injury

  2013cited by this paper
• 12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash.

  2013cited by this paper
• Beyond pattern recognition: NOD-like receptors in dendritic cells.

  2013cited by this paper
• Novel role of PKR in inflammasome activation and HMGB1 release

  2012cited by this paper
• Immune self-reactivity triggered by drug-modified HLA-peptide repertoire

  2012cited by this paper
• Redox Modification of Cysteine Residues Regulates the Cytokine Activity of High Mobility Group Box-1 (HMGB1)

  2012cited by this paper
• ER Stress Activates NF-κB by Integrating Functions of Basal IKK Activity, IRE1 and PERK

  2012cited by this paper
• Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far?

  2012cited by this paper
• The endoplasmic reticulum stress response in aging and age-related diseases

  2012cited by this paper
• Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

  2012cited by this paper
• Roles of LAG3 and EGR2 in regulatory T cells

  2012cited by this paper
• Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.

  2011cited by this paper
• The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation

  2011cited by this paper
• Haptenation: Chemical Reactivity and Protein Binding

  2011cited by this paper
• Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report.

  2011cited by this paper
• The control of adaptive immune responses by the innate immune system.

  2011cited by this paper
• Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH)

  2011cited by this paper
• Disease-associated amyloid and misfolded protein aggregates activate the inflammasome.

  2011cited by this paper
• 2,4-Dinitrophenol (DNP): A Weight Loss Agent with Significant Acute Toxicity and Risk of Death

  2011cited by this paper
• Measuring ER stress and the unfolded protein response using mammalian tissue culture system.

  2011cited by this paper
• HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.

  2011cited by this paper
• Signaling by ROS drives inflammasome activation

  2010cited by this paper
• Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

  2010cited by this paper
• THE FACTS ABOUT PENICILLIN ALLERGY: A REVIEW

  2010cited by this paper
• The Unfolded Protein Response, Degradation from Endoplasmic Reticulum and Cancer.

  2010cited by this paper
• Immune tolerance: what is unique about the liver.

  2010cited by this paper
• Severe Drug-induced Liver Injury Associated with Prolonged Use of Linezolid

  2010cited by this paper
• Heterologous immunity between viruses

  2010cited by this paper
• The inflammasomes: mechanisms of activation and function.

  2010cited by this paper
• Role of the bile salt export pump, BSEP, in acquired forms of cholestasis

  2010cited by this paper
• Polymerase γ Gene POLG determines the risk of sodium valproate‐induced liver toxicity

  2010cited by this paper
• A Study of the Specificity of Lymphocytes in Nevirapine-Induced Skin Rash

  2009cited by this paper
• The inflammasomes: guardians of the body.

  2009cited by this paper
• HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients

  2009cited by this paper
• Endotoxin tolerance: new mechanisms, molecules and clinical significance.

  2009cited by this paper
• HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

  2009cited by this paper
• A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding

  2009cited by this paper
• Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study

  2008cited by this paper
• HLA-B*5701 screening for hypersensitivity to abacavir.

  2008cited by this paper
• Idiosyncratic drug reactions: past, present, and future.

  2008cited by this paper
• The IκBα/NF‐κB complex has two hot spots, one at either end of the interface

  2008cited by this paper
• Drug-induced lupus due to anti-tumor necrosis factor alpha agents.

  2008cited by this paper
• Drug‐induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies

  2008cited by this paper
• The endoplasmic reticulum stress response in immunity and autoimmunity

  2008cited by this paper
• The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors

  2008cited by this paper
• From endoplasmic-reticulum stress to the inflammatory response

  2008cited by this paper
• Idiosyncratic drug reactions: current understanding.

  2007cited by this paper
• Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury

  2007cited by this paper
• A prospective study of acute drug‐induced liver injury in patients suffering from non‐alcoholic fatty liver disease

  2007cited by this paper
• Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity?

  2007cited by this paper
• Bile Acid Transporters: Structure, Function, Regulation and Pathophysiological Implications

  2007cited by this paper
• Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities.

  2007cited by this paper
• Valproate‐Induced Hepatic Injury: Analyses of 23 Fatal Cases

  2007cited by this paper
• Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

  2006cited by this paper
• The Inflammatory Caspases: Key Players in the Host Response to Pathogenic Invasion and Sepsis

  2006cited by this paper
• Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.

  2006cited by this paper
• Rechallenge with clozapine following leucopenia or neutropenia during previous therapy

  2006cited by this paper
• The role of metabolic activation in drug-induced hepatotoxicity.

  2005cited by this paper

• Deciphering the potential molecular mechanism of resmetirom in idiosyncratic drug- induced autoimmune hepatitis using network toxicology and molecular docking

  2026cites this paper
• Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis

  2025cites this paper
• Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitis.

  2025cites this paper
• Proteomic identification of protein radicals from myeloperoxidase-mediated mefenamic acid oxidation reveals a mechanism of NSAID-induced oxidative injury

  2025cites this paper
• A novel quantitative assessment of formed reactive metabolites by double trapping with [3H]glutathione and [14C]cyanide.

  2025cites this paper
• Discovery of Functionalized 1H-Benzo[d]imidazoles That Confer Protective Effects in a Phenotypic CLN3 Disease Patient-Derived iPSC Model.

  2025cites this paper
• Predicting clozapine-induced adverse drug reaction biomarkers using machine learning

  2025cites this paper
• Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury

  2025cites this paper
• Sulforaphane treatment of HL-60 cells protects against clozapine toxicity and protein covalent binding: implications for clozapine-induced agranulocytosis.

  2025cites this paper
• A review on adverse drug reaction related to medication in health sector: an account of what we have discovered and implemented—pharmacovigilance

  2025cites this paper
• The induction of quinone oxidoreductases NQO1 and NQO2 by clozapine: potential implications for clozapine-induced agranulocytosis.

  2025cites this paper
• DILI prediction in drug development: present and future

  2025cites this paper
• Polysaccharides from Dicliptera chinensis (L.) Juss. Attenuates drug-induced liver injury by phosphorylating AMPK and thus facilitating the entry of FOXO3 into the cell nucleus.

  2025cites this paper
• Brigatinib activates inflammasomes: Implication for immune-related adverse events.

  2025cites this paper
• Liver Microphysiological System for Drug‐Induced Liver Injury (DILI) Evaluation Based on Kinetic Pump Integrated Microfluidic Plate (KIM‐Plate)

  2025cites this paper
• In-depth understanding of the structure-based reactive metabolite formation of organic functional groups

  2025cites this paper
• InterDIA: Interpretable Prediction of Drug-induced Autoimmunity through Ensemble Machine Learning Approaches.

  2025cites this paper
• TAK-994 mechanistic investigation into drug-induced liver injury

  2025cites this paper
• Reactive Metabolites Cause Idiosyncratic Drug‐Induced Liver Injury via Inflammasome Activation in Antigen‐Presenting Cells

  2025cites this paper
• Assessing immune hepatotoxicity of troglitazone with a versatile liver-immune-microphysiological-system

  2024cites this paper
• Protein Haptenation and Its Role in Allergy

  2024cites this paper
• The use of PD-1 functional knockout rats to study idiosyncratic adverse reactions to nevirapine.

  2024cites this paper
• The role of corticosterone in nevirapine-induced idiosyncratic drug-induced liver injury.

  2024cites this paper
• Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis

  2024cites this paper
• In vitro and in vivo metabolic activation and hepatotoxicity of chlorzoxazone mediated by CYP3A

  2024influential citation
• Reactive metabolite of trovafloxacin activates inflammasomes: Implications for trovafloxacin‐induced liver injury

  2024cites this paper
• Involvement of Extracellular Vesicles in the Proinflammatory Response to Clozapine: Implications for Clozapine-Induced Agranulocytosis

  2024cites this paper
• The development and characterization of a CRISPR/Cas9-mediated PD-1 functional knockout rat as a tool to study idiosyncratic drug reactions.

  2024cites this paper
• Potential Involvement of Sulfotransferase in the Mechanism of Lamotrigine-induced Skin Rash

  2023cites this paper
• Bioactivation and reactivity research advances – 2022 year in review‡

  2023cites this paper
• Using Proteins As Markers for Anabolic Steroid Abuse: A New Perspective in Doping Control?

  2023cites this paper
• Mechanism of non-steroidal anti-androgen-induced liver injury: Reactive metabolites of flutamide and bicalutamide activate inflammasomes.

  2023cites this paper
• A review of the mechanisms of valproate-induced liver injury with an emphasis on the role of reactive metabolites discovered by Tom Baillie

  2023cites this paper
• Preclinical evaluation of chemically reactive metabolites and mitigation of bioactivation in drug discovery.

  2023cites this paper
• Mitigating a Bioactivation Liability with an Azetidine-Based Inhibitor of Diacylglycerol Acyltransferase 2 (DGAT2) En Route to the Discovery of the Clinical Candidate Ervogastat.

  2023cites this paper
• Advances in Epilepsy: Mechanisms, Clinical Trials, and Drug Therapies.

  2023cites this paper
• Drug Hypersensitivity Reactions in Patients with Cystic Fibrosis: Potential Value of the Lymphocyte Toxicity Assay to Assess Risk

  2023cites this paper
• An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation

  2023cites this paper
• The Role of Myeloperoxidase in Clozapine-Induced Inflammation: A Mechanistic Update for Idiosyncratic Drug-Induced Agranulocytosis

  2023cites this paper
• Cost Savings: Home Versus Inpatient Infusion Therapy, A Review of the Literature

  2023cites this paper
• Cefazolin-Induced Neutropenia Development and Evaluation of Risk Factors in Home Infusion (CINDER-FHI)

  2023cites this paper
• Modifications of the Triaminoaryl Metabophore of Flupirtine and Retigabine Aimed at Avoiding Quinone Diimine Formation

  2022cites this paper
• Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study

  2022cites this paper
• Consideration of predicted small-molecule metabolites in computational toxicology

  2022cites this paper
• Configurational Alteration Results in Change in Hepatotoxicity of Asarone.

  2022cites this paper
• Pathophysiology of drug hypersensitivity

  2022cites this paper
• Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice

  2022cites this paper
• Organ-On-A-Chip Technology: An In-depth Review of Recent Advancements and Future of Whole Body-on-chip

  2022cites this paper
• Development and initial validation of a modified lymphocyte transformation test (LTT) assay in patients with DRESS and AGEP

  2022cites this paper
• Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury

  2022cites this paper
• Distal kinetic deuterium isotope effect: Phenyl ring deuteration attenuates N-demethylation of Lu AF35700.

  2022cites this paper
• Risk Assessment in Drug Hypersensitivity: Detecting Small Molecules Which Outsmart the Immune System

  2022cites this paper
• Idiosyncratic Drug Reactions: A 35-Year Chemical Research in Toxicology Perspective

  2022cites this paper
• Simultaneous quantification of trimethoprim metabolites in pediatric plasma.

  2022cites this paper
• Integration of a microfluidic multicellular coculture array with machine learning analysis to predict adverse cutaneous drug reactions.

  2022cites this paper
• Mitochondria as the Target of Hepatotoxicity and Drug-Induced Liver Injury: Molecular Mechanisms and Detection Methods

  2022cites this paper
• The important role of non‐covalent drug‐protein interactions in drug hypersensitivity reactions

  2021cites this paper
• Liver Injury Caused by Green Tea Extract in PD-1-/- Mice: An Impaired Immune Tolerance Model for Idiosyncratic Drug-Induced Liver Injury.

  2021cites this paper
• Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention.

  2021cites this paper
• The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity

  2021cites this paper
• Lymphocyte transformation test: History and current approaches.

  2021cites this paper
• Model Based Evaluation of Hypersensitivity Adverse Drug Reactions to Antimicrobial Agents in Children

  2021cites this paper
• Drug-Induced Liver Injury

  2021cites this paper
• Future perspectives on in-vitro diagnosis of drug allergy by the lymphocyte transformation test.

  2021cites this paper
• The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions

  2021influential citation
• Amiodarone, Unlike Dronedarone, Activates Inflammasomes via Its Reactive Metabolites: Implications for Amiodarone Adverse Reactions.

  2021cites this paper
• Machine Learning for Predicting Risk of Drug-Induced Autoimmune Diseases by Structural Alerts and Daily Dose

  2021cites this paper
• Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reaction.

  2021cites this paper
• Histological Changes in Renal, Hepatic and Cardiac Tissues of Wistar Rats after 6 Weeks Treatment with Bipyridine Gold (III) Complex with Dithiocarbamate Ligands

  2021cites this paper
• Permeabilized Cryopreserved Human Hepatocytes as an Exogenous Metabolic System in a Novel Metabolism-Dependent Cytotoxicity Assay for the Evaluation of Metabolic Activation and Detoxification of Drugs Associated with Drug-Induced Liver Injuries: Results with Acetaminophen, Amiodarone, Cyclophosphami

  2021cites this paper
• Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury.

  2020cites this paper
• Fit-For-Purpose Hepatocyte Models Enable the Identification of Early Events Contributing to Idelalisib-Induced Liver Injury

  2020cites this paper
• Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.

  2020cites this paper
• Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction.

  2020cites this paper
• Use of Ketamine in Sphynx Cats

  2020cites this paper
• Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ.

  2020cites this paper
• Approaches to mitigate the risk of serious adverse reactions in covalent drug design

  2020cites this paper
• Screening trimethoprim primary metabolites for covalent binding to albumin

  2020cites this paper
• Designing Around Structural Alerts in Drug Discovery.

  2020cites this paper
• Drug–protein adducts: past, present, and future

  2020cites this paper
• Cyanopyrrolidine Inhibitors of Ubiquitin Specific Protease 7 Mediate Desulfhydration of the Active-Site Cysteine.

  2020cites this paper
• The hepatotoxicity of Polygonum multiflorum: The emerging role of the immune-mediated liver injury

  2020cites this paper
• Is There Enough Evidence to Classify Cycloalkyl Amine Substituents as Structural Alerts?

  2020cites this paper
• THE EFFECTIVE APPLICATION OF METABOLITE PROFILING IN DRUG DESIGN AND DISCOVERY.

  2020cites this paper
• Cutaneous Adverse Events Caused by Sulfonamide-Containing Drugs: Reality or Perception?

  2020cites this paper
• Role of Oxidative Stress in Hypersensitivity Reactions to Sulfonamides

  2019cites this paper
• Detection and phenotypic characterization of drug (metabolite)-specific t-cells from patients with drug-induced skin and liver injury and healthy donors

  2019cites this paper
• Reproducing human and cross-species drug toxicities using a Liver-Chip

  2019cites this paper
• Carbamazepine promotes specific stimuli-induced NLRP3 inflammasome activation and causes idiosyncratic liver injury in mice

  2019cites this paper
• Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors

  2019cites this paper
• Hepatic Bioactivation of Skin-Sensitizing Drugs to Immunogenic Reactive Metabolites

  2019cites this paper
• Bioactivation of herbal constituents: mechanisms and toxicological relevance

  2019cites this paper
• The 2-Hydroxyiminostilbene Metabolite of Carbamazepine or the Supernatant from Incubation of Hepatocytes with Carbamazepine Activates Inflammasomes: Implications for Carbamazepine-Induced Hypersensitivity Reactions

  2019cites this paper
• Rotenone Increases Isoniazid Toxicity but Does Not Cause Significant Liver Injury: Implications for the Hypothesis that Inhibition of the Mitochondrial Electron Transport Chain Is a Common Mechanism of Idiosyncratic Drug-Induced Liver Injury.

  2019cites this paper
• Role of intestinal microbiota-mediated genipin dialdehyde intermediate formation in geniposide-induced hepatotoxicity in rats.

  2019cites this paper
• Liver-Chip: Reproducing Human and Cross-Species Toxicities

  2019cites this paper
• Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity

  2019cites this paper
• Short Communication The 2-Hydroxyiminostilbene Metabolite of Carbamazepine or the Supernatant from Incubation of Hepatocytes with Carbamazepine Activates Inflammasomes: Implications for Carbamazepine-Induced Hypersensitivity Reactions s

  2019cites this paper
• Short Communication The 2-Hydroxyiminostilbene Metabolite of Carbamazepine or the Supernatant from Incubation of Hepatocytes with Carbamazepine Activates Inflammasomes: Implications for Carbamazepine-Induced Hypersensitivity Reactions s

  2019cites this paper
• Short Communication The 2-Hydroxyiminostilbene Metabolite of Carbamazepine or the Supernatant from Incubation of Hepatocytes with Carbamazepine Activates Inflammasomes: Implications for Carbamazepine-Induced Hypersensitivity Reactions s

  2019cites this paper